^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

HMG-CoA reductase inhibitor

3d
New P1/2 trial
|
atorvastatin
3d
Impact of Statin Therapy on Adaptations to Aerobic Exercise (clinicaltrials.gov)
P4, N=119, Completed, University of Kansas Medical Center | Active, not recruiting --> Completed
Trial completion
|
atorvastatin
3d
SHOT: Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment (clinicaltrials.gov)
P4, N=240, Active, not recruiting, Chiayi Christian Hospital | Recruiting --> Active, not recruiting
Enrollment closed
|
atorvastatin
3d
Chronic Coronary Syndrome Real Practice and Guidelines (clinicaltrials.gov)
P=N/A, N=300, Active, not recruiting, Assiut University
New trial
|
simvastatin • atorvastatin
5d
New trial
|
atorvastatin
5d
Clinical study of precise anti-plate and enhanced lipid-lowering in acute disabling TIA/ mild stroke (ChiCTR2400088950)
P=N/A, N=302, Not yet recruiting, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University; The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University
New trial
|
APOA1 (Apolipoprotein A-I) • APOB (Apolipoprotein B)
|
atorvastatin
10d
New trial
|
atorvastatin
11d
A Case of Statin-Induced Necrotizing Autoimmune Myopathy. (PubMed, Cureus)
A 65-year-old woman with a past medical history of hyperlipidemia on atorvastatin for four years, type 2 diabetes, sciatica, and a prior history of endometrial cancer, presented to the emergency department due to proximal muscle weakness worsening over 2-3 months...During her hospital course, she was started on prednisone, fluids, and intravenous immunoglobulin (IVIG). Once completing two days of IVIG, the patient was discharged to rehab with rheumatology follow-up. The purpose of this case is to elucidate a rare side effect of a medication despite being on it for several years and to increase awareness and attention to an adverse effect that may one day lead to stratifying patients' risk on the medication.
Journal
|
CRP (C-reactive protein)
|
prednisone • atorvastatin
11d
Are we better together? Addressing a combined treatment of pitavastatin and temozolomide for brain cancer. (PubMed, Eur J Pharmacol)
The obtained qRT-PCR and proteomics data highlight the modulation of cell death via apoptosis (BAX/BCL2, CASP9) and autophagy (BECN1, BNIP3, BNIP3L and LC3B), as well as an epithelial to mesenchymal transition blockage (HTRA1, SERPINE1, WNT5A, ALDH3B1 and EPHA2) and remodeling of the extracellular matrix (VCAN, SERPINE1 and TGFBI). Overall, these results lay the foundation for further investigations on the potential combinatory clinical treatment with temozolomide.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • BNIP3L (BCL2 Interacting Protein 3 Like) • CASP9 (Caspase 9) • SERPINE1 (Serpin Family E Member 1) • TGFBI (Transforming Growth Factor Beta Induced) • BECN1 (Beclin 1) • HTRA1 (HtrA Serine Peptidase 1)
|
temozolomide • pitavastatin
17d
Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet (clinicaltrials.gov)
P1/2, N=22, Enrolling by invitation, Johns Hopkins University | Not yet recruiting --> Enrolling by invitation
Enrollment open
|
atorvastatin
23d
Inflammatory profile of eosinophils in asthma-COPD overlap and eosinophilic COPD: a multi-omics study. (PubMed, Front Immunol)
Atorvastatin, dexamethasone, and PGE2 differentially modulated these inflammatory changes. ACO/eCOPD is associated with viral infection and an inflammatory milieu. Therapeutic strategies using statins and inhaled corticosteroids are recommended to control these pathogenic changes.
Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • FCER1G (Fc Fragment Of IgE Receptor Ig) • IL5 (Interleukin 5) • IL33 (Interleukin 33)
|
dexamethasone • atorvastatin
27d
Glucose and pH dual-responsive hydrogels with antibacterial, reactive oxygen species scavenging, and angiogenesis properties for promoting the healing of infected diabetic foot ulcers. (PubMed, Acta Biomater)
The multifunctional QO/@PV@AB7 hydrogel was prepared by incorporating pravastatin-loaded chitosan nanoparticles (CSNPs@PV, 2 mg/mL) and antimicrobial peptide AMP-AB7 loaded silica nanoparticles (SiO2NPs@AB7, 0.5 mg/mL)...Notably, it also demonstrates potent antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli. Additionally, in vivo experiments demonstrated that the hydrogel exhibited accelerated wound healing in MRSA-infected diabetic foot ulcers, with a reduction of four days compared to the control group.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • CD31 (Platelet and endothelial cell adhesion molecule 1) • NOS3 (Nitric oxide synthase 3) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
29d
Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial (clinicaltrials.gov)
P1/2, N=80, Active, not recruiting, University of Chicago | Trial completion date: Jun 2025 --> Mar 2025
Trial completion date
|
atorvastatin
29d
Microneedles integrated with atorvastatin-loaded pumpkisomes for breast cancer therapy: A localized delivery approach. (PubMed, J Control Release)
Thus, our study presents PUMP as a novel and promising bioactive vesicular nanosystem with potential synergistic effect with ATV or other antitumor drugs. PUMP-integrated MN could be considered a promising platform for future applications in localized breast cancer therapy.
Journal • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
atorvastatin
29d
2'3'-cGAMP interactome identifies 2'3'-cGAMP/Rab18/FosB signaling in cell migration control independent of innate immunity. (PubMed, Sci Adv)
Induced synthesis of endogenous 2'3'-cGAMP by intrabreast tumor bacterium S. aureus infection or low-dose doxorubicin treatment facilitates cell migration depending on the cGAS/cGAMP/Rab18/FosB signaling. We find that lovastatin induces Rab18 deprenylation that abolishes 2'3'-cGAMP recognition therefore suppressing cell migration. Together, our study reveals a previously unidentified 2'3'-cGAMP function in cell migration control via the 2'3'-cGAMP/Rab18/FosB signaling that provides additional insights into clinical applications of 2'3'-cGAMP.
Journal
|
STING (stimulator of interferon response cGAMP interactor 1)
|
doxorubicin hydrochloride • lovastatin
30d
Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial (clinicaltrials.gov)
P1/2, N=80, Active, not recruiting, University of Chicago | Trial primary completion date: Dec 2024 --> Jul 2024
Trial primary completion date
|
atorvastatin
1m
Enrollment change
1m
Letter to the editor: Comment on "possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial". (PubMed, Med Oncol)
Furthermore, we propose metabolomic analysis to uncover the drug's mechanisms of action and computational methods like molecular docking to predict its potential targets, which could refine drug design and inform personalized treatment strategies. Our commentary aims to refine the study's conclusions and encourage research that maximizes the understanding and clinical management of chemotherapy-induced cardiotoxicity.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • ROS1 positive
1m
Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma (clinicaltrials.gov)
P2, N=150, Recruiting, OHSU Knight Cancer Institute | Trial completion date: Mar 2029 --> Sep 2029
Trial completion date
|
atorvastatin
1m
New P4 trial
|
atorvastatin
1m
New P2 trial
|
simvastatin
1m
Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia (clinicaltrials.gov)
P2, N=38, Recruiting, Peking University People's Hospital | Trial completion date: Feb 2025 --> Jun 2025
Trial completion date
|
medroxyprogesterone • atorvastatin
1m
Pravastatin prevents colitis-associated carcinogenesis by reducing CX3CR1high M2-like fibrocyte counts in the inflamed colon. (PubMed, Sci Rep)
Statin treatment after azoxymethane/dextran sulfate sodium-induced inflammation reduced CX3CR1high fibrocyte counts and suppressed colitis-associated CRC. Therefore, CX3CR1high fibrocytes represent a potential target for carcinogenesis-preventing therapy, and statins could be safe therapeutic candidates for IBD.
Journal
|
COL1A1 (Collagen Type I Alpha 1 Chain) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • SLAMF7 (SLAM Family Member 7)
1m
The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer (clinicaltrials.gov)
P2, N=26, Recruiting, Indonesia University | Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Aug 2024 --> May 2025
Trial completion date • Trial primary completion date
|
VIM (Vimentin)
|
VIM expression
|
simvastatin
1m
Trial termination
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative
|
capecitabine • atorvastatin
1m
Systems Biological Assessment of Statin Effect on Vaccine Responses (clinicaltrials.gov)
P4, N=86, Active, not recruiting, Emory University | Recruiting --> Active, not recruiting | N=60 --> 86 | Trial completion date: Mar 2026 --> Dec 2025 | Trial primary completion date: Mar 2026 --> Dec 2025
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
atorvastatin
2ms
Association of Wild-Type TP53 with Downregulation of Lovastatin Sensitivity in Human Non-Small Cell Lung Cancer Cells. (PubMed, Curr Issues Mol Biol)
Docetaxel (DOC) is a microtubule-stabilizing agent currently used as a chemotherapeutic drug in several cancers, including lung cancer...Mutated or null TP53 status is correlated with higher statin sensitivity. Furthermore, DOC-resistant H1299 (H1299/D8) cells showed significant sensitivity to lovastatin treatment compared to DOC-resistant A549 (A549/D16) cells, indicating a potential application of statins/chemotherapy combination therapy to control wild-type and abnormal TP53-containing human lung tumors.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 wild-type • TP53 expression
|
docetaxel • lovastatin
2ms
Trial termination • Biopsy
|
atorvastatin
2ms
Treatment of Graves´ophthalmopathy with Simvastatin (GO-S) (clinicaltrials.gov)
P3, N=80, Recruiting, Lund University | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
Trial completion date • Trial primary completion date
|
simvastatin
2ms
Simvastatin induces ferroptosis and activates anti-tumor immunity to sensitize anti-PD-1 immunotherapy in microsatellite stable gastric cancer. (PubMed, Int Immunopharmacol)
Our data revealed the significance of cholesterol synthesis in GC and demonstrated simvastatin served as a promising sensitizer for ICB therapy by inducing ferroptosis and anti-tumor immunity in MSS GC patients.
Journal
|
CD8 (cluster of differentiation 8)
|
simvastatin
2ms
Zhuyu Pills regulate p53/SLC7A11 signaling pathway-mediated oxidative damage and ferroptosis to treat atherosclerosis (PubMed, Zhongguo Zhong Yao Za Zhi)
Compared with the model group, low-, medium-, and high-dose Zhuyu Pills and atorvastatin calcium reduced the aortic plaque area, collagen deposition, liver lipid deposition, lipid droplets, and epididymal adipocyte volume, lowered the levels of iron ion and MDA and elevated the levels of SOD and GSH-Px in the serum, inhibited the expression of p53 and COX2, up-regulated the protein and mRNA levels of FTH1, SLC7A11, and GPX4, and down-regulated the mRNA levels of PTGS2 and NOX1 in the aorta. In conclusion, Zhuyu Pills exert definite therapeutic effect on aortic plaque in AS mice by regulating the p53/SLC7A11 signaling pathway to alleviate oxidative damage and inhibit ferroptosis.
Journal
|
GPX4 (Glutathione Peroxidase 4) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • SLC7A11 (Solute Carrier Family 7 Member 11) • APOE (Apolipoprotein E) • MT-CO2 (Mitochondrially Encoded Cytochrome C Oxidase II) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
|
TP53 expression
|
atorvastatin
2ms
Targeting ferroptosis for improved radiotherapy outcomes in HPV-negative head and neck squamous cell carcinoma. (PubMed, Mol Oncol)
Furthermore, our in vitro and in vivo studies demonstrated that treatment with statins, such as atorvastatin and simvastatin, induced ferroptosis and sensitized radioresistant HNSCC cells to irradiation, improving radiosensitivity and potentially enhancing the response to RT. Additionally, in xenograft models, the combination of statins and RT led to a significant reduction in tumor initiation. These findings provide valuable insights for enhancing treatment and improving prognosis in HPV-negative HNSCC by targeting ferroptosis and utilizing statins to sensitize tumors to RT-induced cell death.
Journal
|
NCOA4 (Nuclear Receptor Coactivator 4) • GPX4 (Glutathione Peroxidase 4) • DMRT1 (Doublesex And Mab-3 Related Transcription Factor 1)
|
simvastatin • atorvastatin
2ms
MS-STAT2: Multiple Sclerosis-Simvastatin Trial 2 (clinicaltrials.gov)
P3, N=964, Completed, University College, London | Active, not recruiting --> Completed
Trial completion
|
simvastatin
2ms
A randomized, double-blind, placebo-controlled, dual-center clinical study to evaluate the efficacy and safety of pitavastatin calcium dispersible tablets in the treatment of active systemic lupus erythematosus (ChiCTR2400084812)
P=N/A, N=30, Not yet recruiting, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College.; Hospital for Skin Disea | N=10 --> 30
Enrollment change
|
pitavastatin
2ms
Ultra-early STatin in patients with Aneurysmal subaRachnoid hemorrhage (Ue-STAR): a randomized controlled trial (ChiCTR2400088277)
P=N/A, N=522, Not yet recruiting, Tianjin Medical University General Hospital; Tianjin Medical University General Hospital
New trial
|
atorvastatin
2ms
A multicenter randomized controlled trial of acupuncture treatment for recurrent ischemic stroke with vertigo (ChiCTR2400087030)
P1, N=228, Not yet recruiting, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine; Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
New P1 trial
|
atorvastatin • aspirin
2ms
A Study of LY4065967 in Healthy Japanese Participants (clinicaltrials.gov)
P1, N=69, Not yet recruiting, Eli Lilly and Company
New P1 trial
2ms
Clinical Effects of New Approach on Patients with Non-alcoholic Steatohepatitis (clinicaltrials.gov)
P1, N=175, Completed, Beni-Suef University | Recruiting --> Completed | Trial completion date: Jan 2025 --> Jun 2024 | Trial primary completion date: Oct 2024 --> Jun 2024
Trial completion • Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase) • NLRP3 (NLR Family Pyrin Domain Containing 3)